level-one heading

Writers
Data Analysts
Consultants
Product Developers
Researchers
Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 90 /hr
Hire Dr. Krishnaa U.
India
USD 90 /hr

Clinical Pharmacologist | Clinical Research & Drug Development Expert | ICH-GCP, USFDA, EMA Compliance | Medical & Scien

Profile Summary
Subject Matter Expertise
Services
Writing Clinical Trial Documentation, Medical Writing
Research Market Research, Feasibility Study
Consulting Business Strategy Consulting
Work Experience

Director

Krescent Medical Research Pvt Ltd

February 2021 - Present

Education

PhD (Pharmacology)

Sunrise University

February 2020 - January 2024

Master (Clinical Pharmacy)

NMIMS School of Pharmacy and Technology Management

August 2009 - August 2011

Certifications
Publications
JOURNAL ARTICLE
e: Upadhye KS, Tayade P, Patidar H. Resmetirom: A promising treatment for no n-alcoholic steatohepatitis. Am J Pharmacother Pharm Sci 2025:010 .
Krishna U, Paritosh T, Hariom P, Narendra Y. The impact of gut microbiota in the development and management of diabetes. J Diabetol 2025;16:193-203 .
Upadhye KS, Patidar H. Anemia management strategies in diabetic kidney disease: A comprehensive review. J Diabetol 2025;16:93-101 .
Upadhye KS, Patidar H, Bamnia N, Yadav N. HbA1c reduction strategies: An overview of pharmacological interventions. Natl J Pharmacol Ther 2025;3:24-33 .
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav (2025). Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis . Indian Journal of Rheumatology.
Upadhye, K.S., Tayade, P., Patidar, H., Yadav, N.(2025). Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis . Indian Journal of Rheumatology.
Upadhye, K.S., Patidar, H.(2025). Anemia Management Strategies in Diabetic Kidney Disease: A Comprehensive Review . Journal of Diabetology. 16. (2). p. 93-101.
Roy R, Vivek B, Krishna Upadhye (2024). EVALUATING PRESCRIPTION PATTERNS IN SURGICAL WARD: A CROSS-SECTIONAL ANALYSIS OF A RESEARCH CONDUCTED AT A SINGLE MEDICAL CENTER . EPRA International Journal of Multidisciplinary Research (IJMR).
(2024). EVALUATING THE APPREHENSIONS ABOUT THE EXCESSIVE UTILIZATION OF ANTI-SECRETORY MEDICATION CONSUMPTION . GJRA - GLOBAL JOURNAL FOR RESEARCH ANALYSIS.
Roy R, Vivek B, Krishna Upadhye (2024). TO EVALUATE THE PREVALENCE OF ANTISECRETORY MEDICATION USE AMONG HOSPITALIZED PATIENTS IN SURGERY WARD . EPRA International Journal of Research & Development (IJRD).
Krishna Upadhye, Dr. Uttam Kumar Aggarwal (2024). HEMATOLOGICAL DYNAMICS IN HEMODIALYSIS: A COMPREHENSIVE EXAMINATION OF PATIENTS WITH CHRONIC RENAL FAILURE IN A TERTIARY CARE HOSPITAL . EPRA International Journal of Multidisciplinary Research (IJMR).
(2024). FROM TREATMENT TO CHALLENGE: EXPLORING STEROID-INDUCED DIABETES MELLITUS – A COMPREHENSIVE CASE STUDY . PARIPEX - INDIAN JOURNAL OF RESEARCH.
Krishna Upadhye, “Anemia Prevalence and Its Correlations With Renal Function and Quality of Life in Diabetic Kidney Disease Patients," International Journal for Innovative Engineering and Management Research, Volume 12, Issue 01, Pages 979–984 (2023) .
Krishna Upadhye, “Exploring the Epidemiology and Association of Anemia in Diabetic Kidney Disease: A Comprehensive Analysis Of Patient Data," International Journal for Advanced Research in Science & Technology, Volume 12, Issue 7July 2022, https://www.ijarst.in/public/uploads/paper/730171698656914.pdf .
Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis @article{doi:10.1177/09733698251316343,author={Krishna. S Upadhye and Paritosh Tayade and Hariom Patidar and Narendra Yadav},title={Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis},journal={Indian Journal of Rheumatology},volume={0},number={0},pages={09733698251316343},year={0},doi={10.1177/09733698251316343},URL={https://doi.org/10.1177/09733698251316343 },eprint={https://doi.org/10.1177/09733698251316343 },abstract={This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to traditional disease-modifying antirheumatic drugs (DMARDs) and other JAK inhibitors. Authors conducted a systematic search of PubMed, Scopus and Google Scholar to identify relevant studies, including phase I, II, and III clinical trials. We extracted and synthesised data on efficacy end points (ACR20, ACR50, and ACR70), safety profiles, and long-term outcomes. We performed comparative analyses with traditional DMARDs and other JAK inhibitors. Filgotinib demonstrates high efficacy in RA management, with ACR20 response rates ranging from 70\% to 80\%, ACR50 from 40\% to 50\%, and ACR70 from 20\% to 30\%. It significantly reduces disease activity (as measured by DAS28-CRP) and improves physical function (as indicated by Health Assessment Questionnaire Disability Index [HAQ-DI] scores). Compared to traditional DMARDs, filgotinib offers superior efficacy and a favourable safety profile. In comparison to other JAK inhibitors, filgotinib’s selective JAK1 inhibition contributes to a similar or improved safety profile while maintaining high efficacy. Long-term data confirm its sustained benefits and manageable safety profile. Filgotinib is a promising treatment option for RA, offering significant benefits. Clinical trials have observed improvements in disease activity and quality of life. Its selective JAK1 inhibition and favourable safety profile make it a competitive alternative to both traditional DMARDs and other JAK inhibitors. Ongoing research into personalised medicine and emerging therapies will further define filgotinib’s role in RA management. }} . Indian Journal of Rheumatology.